A r t i c l e s were unaffected, and segregation analysis for eight cases where both parental DNA samples were available showed that in each case the mutation occurred de novo ( Fig. 2a and Supplementary Fig. 2 ). Genotyping a set of microsatellite markers in five trios with sufficient DNA available confirmed that the pedigrees were correct. One of the index cases (PME84-1) with the c.959G>A mutation had an affected sibling and two affected children, who were also each heterozygous for the mutation (Fig. 2a) . The parents of PME84-1 and her unaffected brother were both negative for the mutation. The presence of two mutation-positive and clinically affected children from mutation-negative, unaffected parents suggests the occurrence of mosaicism in one of the parents. A restriction fragment length assay designed to detect both the normal and mutant alleles was carried out on peripheral blood DNA from both parents but showed no indication of mosaicism (data not shown).
We screened for the KCNC1 c.959G>A mutation in a secondary cohort of 28 PME cases and identified 2 (7.1%) additional unrelated cases heterozygous for the mutation. Sanger sequencing of the available parental samples of one of these individuals confirmed the de novo occurrence of the mutation (Fig. 2a) . In total, we identified 16 cases (13 unrelated) with the c.959G>A mutation. We did not identify any other mutations in KCNC1 in the exome data. As exon 1 was not sufficiently covered, we carried out Sanger sequencing of it in the 73 exome-sequenced c.959G>A-negative cases, but no potentially deleterious variants were found.
The c.959G>A mutation in KCNC1 affects a highly evolutionarily conserved arginine residue in segment S4, constituting the main voltage-sensing domain of the channel (Fig. 2b,c) . The mutation was predicted to be deleterious by all four in silico methods used (Supplementary Table 3 ). Table 1) . After filtering the raw variant data for possible pathogenic variants, we first analyzed the data for mutations in genes known to be associated with PME, epilepsy or neurodegenerative diseases and then performed analysis for new disease-related genes under both the recessive and dominant/de novo models. Analysis of the filtered variant data under the recessive model (Fig. 1a,b) identified pathogenic or probably pathogenic mutations (see the Online Methods for classification criteria) in known disease-causing genes in 12 cases. Analysis under the dominant/de novo model (Fig. 1a,b) led to the discovery of a new PME-associated gene, KCNC1, with, remarkably, the same recurrent de novo mutation in 11 cases and, in addition, identified pathogenic mutations in known disease-related genes in 3 cases. We did not identify any obvious pathogenic mutations in mtDNA. In total, we identified pathogenic or probably pathogenic mutations in 26 of 84 cases (31.0%).
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Identification of a recurrent mutation in KCNC1
To identify new pathogenic mutations under the dominant/de novo model, we analyzed the data for potentially deleterious heterozygous variants that were absent in three variant databases. In addition, we did not consider variants in dbSNP except for those with a clinical association in the ClinVar database.
The highest number of new heterozygous variants occurred in KCNC1 together with TTN (Supplementary Table 2 ). TTN encodes a large muscle protein and has a high mutational load 10 owing to its large coding region, and this gene was thus not considered further. We identified 11 (13.1%) unrelated cases with a new heterozygous c.959G>A mutation in KCNC1 (Supplementary Fig. 1 ; Ensembl, ENST00000265969.6), which encodes potassium voltage-gated channel (K V ) subfamily C member 1 (KCNC1, also known as K V 3.1). The c.959G>A mutation causes a substitution of histidine for arginine at codon 320 of the K V 3.1 protein (p.Arg320His).
In all 11 cases, the mutation was confirmed by Sanger sequencing. The parents of all the cases positive for the c.959G>A mutation 
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To assess the frequency of PME due to KCNC1 c.959G>A mutation, we used a newly published mutational model 10 , which takes into account both the local sequence context of a mutation site and regional factors such as divergence between humans and macaques, to estimate the rate of this specific mutation. A rate of 1.75 × 10 −7 mutations per person was obtained, indicating that the mutation should occur in 1 out of every 5,700,000 conceptions. Additionally, we examined three other potential mutations encoding changes of the conserved voltage-sensing arginine residues to histidine in segment S4 of K V 3.1 (p.Arg311His, p.Arg314His and p.Arg317His). Given that the sequence context of the four potential mutations is the same (they all occur in highly mutable CGC codons), the same estimated rate applied to all of them. If all 4 caused PME with equal penetrance, the probability of seeing only 1 of the 4 possible mutations in 13 of 13 independent cases is P = 4 × (1/4) 13 = 6.0 × 10 −8 , strongly suggesting that the effect of p.Arg320His is surprisingly specific for PME. The four positively charged arginine residues (Arg311, Arg314, Arg317, Arg320) occurring every third position are highlighted in blue. The K V 3.3 residues Arg420, Arg423 and Thr428, mutated in spinocerebellar ataxia 24, 25, 27 , are in red boxes. Asterisks, colons and periods indicate fully conserved, strongly similar and weakly similar residues, respectively. (b) Relative current amplitudes of the wild-type channel (n = 49) and Arg320His mutant (n = 50) analyzed at the end of the voltage step to +60 mV and normalized to the mean current amplitude of the wild-type channel recorded on the same day (Mann-Whitney U test, ***P < 0.001). (c) Protein blot analysis of X. laevis oocytes injected with cRNA for either the wild-type channel or the Arg320His mutant using a mouse antibody to the DDK tag. Water-injected oocytes were used as a negative control, and actin served as a loading control. The presence of two bands on the blot is likely to be due to N-glycosylation of the K V 3.1 protein (expected protein size of ~56 kDa), which occurs in in vivo and in heterologous expression systems 50, 51 . (d) Representative whole-cell currents from oocytes injected with a constant amount of cRNA for wild-type channel and either water or cRNA encoding Arg320His mutant in a 1:1 ratio, recorded as in a. (e) Relative current amplitudes remaining upon addition of Arg320His mutant to the wild-type channel (n = 27) were determined at the end of a 0.5-s pulse to +60 mV and normalized to the mean current amplitude for the wild-type channel coinjected with water (n = 32) recorded on the same day (Student's t test, ***P < 0.001). (f) The current-voltage relationships of cells expressing wild-type channel alone or the wild-type and Arg320His channels (Student's t test, P < 0.001 for −60 mV to +50 mV). Lines represent fits of a Boltzmann function. The potential of half-maximal activation (V 0.5 ) was 19.6 ± 0.5 mV (n = 19) and 8.0 ± 1.3 mV (n = 16) (Student's t test, P < 0.001) and the slope factor k was 12.9 ± 0.2 and 10.2 ± 0.3 (Student's t test, P < 0.001) for wild-type channel alone and the wild-type and Arg320His channels together, respectively. The data in b,e and f are presented as means ± s.e.m.
A r t i c l e s automated two-electrode voltage clamp. Potassium currents were recorded from oocytes injected with identical amounts of wild-type or mutant cRNA for the human K V 3.1 channel. Whereas the wild-type channel produced robust currents upon membrane depolarization, the currents observed with the mutant channel were barely detectable (Fig. 3a,b) . Immunoblot analysis using an antibody to the DDK tag with which both proteins were fused showed similar protein levels in the total lysates of oocytes expressing the wild-type or mutant subunit, indicating that the mutant protein had similar stability to the wildtype protein (Fig. 3c) . To look for a possible interaction of the mutant subunit with the wild-type protein, we coexpressed the proteins at a 1:1 ratio. In these experiments, there was an approximately 80% reduction in the expected current amplitude recorded at +60 mV, indicating a dominant-negative effect of the mutant channel (Fig. 3d,e) . The diminished currents resulting from the combination of the mutant and wild-type subunits demonstrated altered gating properties, with a significant hyperpolarizing shift of the activation curve (P < 0.001; Fig. 3f ).
The clinical phenotype of cases with the KCNC1 mutation
We obtained detailed clinical data for 15 of the 16 individuals positive for the KCNC1 mutation ( Table 1 ). The clinical phenotypes were similar and, at disease onset, resembled classic ULD. On a background of usually normal development, the first symptom in the majority of individuals was myoclonus (sometimes reported as tremor) at ages of 6-14 years. Ataxia developed early in one case (PME17-1), but it was otherwise overshadowed by myoclonus as the major motor impediment. There were infrequent tonic-clonic seizures in all cases. During adolescence, myoclonus generally became very severe, limiting ambulation; a walking aid or wheelchair was needed by mid to late teens. Learning disability before seizure onset was noted in some cases, in particular, the nuclear family of PME84-1. There was mild cognitive decline in seven subjects in early adolescence, but this was difficult to quantify owing to the severe motor disability. Early death was not observed. Electroencephalogram recordings showed generalized epileptiform discharges, with photosensitivity in some cases. Magnetic resonance imaging (MRI) scans had no specific features and were regarded as normal or showed cerebellar atrophy. The clinical picture in the family with four affected members (PME84) was milder, with the two older sisters ambulant in the fourth decade of life. Similarly, case 1 from the secondary cohort had a less severe clinical course than the majority of cases.
Mutations in known disease genes
Analysis for mutations in genes known to be associated with PME, epilepsy and neurodegenerative disease identified either pathogenic or probably pathogenic mutations in 15 of the 84 exome-sequenced cases ( Table 2; see Supplementary Table 4 for clinical details as well as summaries of the genetic findings, Supplementary Fig. 3 for pedigrees with segregation data and Supplementary Figs. 4 and 5 for conservation of the newly identified mutation sites). These genes fell into three groups.
First, ten cases had a recessively inherited or de novo heterozygous mutation in established PME-related genes, seven with atypical clinical presentations. The ten comprised three cases of Lafora disease (NHLRC1 (ENST00000340650.3) and EPM2A (ENST00000367519.3)), three cases of sialidosis (NEU1; ENST00000375631.4) and one case of neuronal ceroid lipofuscinosis (CLN6; ENST00000249806.5). Two Italian cases, not known to be related, had the same new homozygous missense AFG3L2 mutation (c.1875G>A; p.Met625Ile; ENST00000269143.3) affecting the proteolytic domain of the protein (Supplementary Fig. 4e ). Exome data showed that they shared a ~1.75-Mb run of identical homozygous polymorphisms flanking the mutation, indicating that the mutation was identical by descent. The tenth case had a de novo previously described 11 pathogenic heterozygous missense mutation (c.1175G>A; p.Gly392Glu; ENST00000295777.5) in the SERPINI1 gene encoding neuroserpin. Mutations in both AFG3L2 and SERPINI1 are very rare known causes of PME.
Second, four cases had mutations in known genes where PME has not been reported as a key part of clinical presentation. One case with adult-onset PME and a father who had died of a similar disease was found to have a previously described 12 pathogenic heterozygous missense mutation (c.305C>T; p.Pro102Leu; ENST00000379440.4) in the PRNP gene encoding prion protein. The mutation is a [16] [17] [18] [19] [20] .
Third, in one case, we identified a previously seen 21 pathogenic heterozygous mutation (c.677C>T; p.Thr226Met; ENST00000303395.4) in SCN1A, the major gene underlying severe myoclonic epilepsy of infancy (Dravet syndrome) 22 . The eventual clinical evolution of this case was typical of Dravet syndrome and not PME. Initial consideration of PME as a clinical diagnosis was due to the predominance of myoclonic seizures in the early disease course.
All variants passing filtering in the known disease-related genes, including the ones not considered to be pathogenic or probably pathogenic, are listed in Supplementary Tables 5 (recessive) and 6 (dominant/de novo). 
Search for additional genes with new mutations
We analyzed the exome data set for potential new PME-associated genes aside from KCNC1, using both recessive and dominant/de novo models. We did not identify other likely new genes using our criteria of observing putative mutations in a gene in at least two unsolved cases under the recessive model or in at least four unsolved cases using the dominant/de novo model (Supplementary Tables 2 and 7 , and Supplementary Note). However, genes of interest in single cases that would warrant further exploration include ALG10 and APOA1BP, which harbored homozygous loss-of-function mutations (Supplementary Table 8 ).
DISCUSSION
Using an exome sequencing approach in a clinically heterogeneous cohort of 84 unrelated individuals with PME without a specific cause, we reached a genetic diagnosis in 31% of the cases. Notably, we identified a recurrent mutation in KCNC1 as a new cause of PME that explained a substantial proportion of cases. KCNC1 encodes K V 3.1, which functions as a highly conserved 23 potassium ion channel subunit of the K V 3 subfamily of voltage-gated tetrameric potassium ion channels. Although KCNC1 mutations have not been associated with human disease until now, mutations inherited in an autosomal dominant manner or occurring de novo in KCNC3 (K V 3.3) cause spinocerebellar ataxia [24] [25] [26] [27] . K V 3 channel subunits consist of six membrane-spanning segments (S1-S6), have overlapping expression patterns and can form heterotetramers 28 . S4 constitutes the main voltage sensor where specific positively charged arginine residues contribute to the gating charge 29, 30 . Electrophysiological analysis showed that the PME-causing p.Arg320His substitution, which affects one of the voltage-sensing residues, causes prominent loss of function with a dominant-negative effect on wild-type K V 3.1 channels. We also observed altered gating properties for the mutant protein, but the physiological consequence of this finding is questionable, as the overall contribution of these altered properties to K V 3.1-mediated current is minor. Similar biophysical properties have been reported for an ataxia-causing alteration in K V 3.3, p.Arg423His 31 , occurring in the position analogous to p.Arg320His in K V 3.1. Mutations affecting positively charged residues in segment S4 of voltage-gated cation channels might contribute to pathogenicity by generating leak currents through the gating pore 32 . For example, in the Drosophila Shaker K V channel, the change analogous to p.Arg320His in K V 3.1 increases proton permeability 33 . However, gating pore currents are not detectable for the analogous K V 3.3 mutant 31 , calling into question the importance of the phenomenon in the context of K V 3.1. Given the ability of K V 3 subunits to form heterotetramers, the dominant-negative Arg320His K V 3.1 mutant is likely to disrupt all K V 3-mediated currents of the neurons in which it is expressed. Reflecting functional redundancy, Kcnc1 and Kcnc3 knockout mice have relatively mild phenotypes, whereas double-mutant mice show myoclonus, tremor and gait ataxia [34] [35] [36] . Thus, the dominant-negative K V 3.1 and K V 3.3 mutations identified in cases seem to have an effect comparable to double knockout in mice.
The K V 3 subfamily is distinguished from other K V channels by more positively shifted voltage-dependent activation and faster activation and deactivation rates. These differences make K V 3 channels major determinants of high-frequency firing in several types of central nervous system (CNS) neurons 28 . Studies using mutant or pharmacologically suppressed K V 3 channels have demonstrated that loss of K V 3 function disrupts the firing properties of fast-spiking neurons 28,37,38 , affects neurotransmitter release 39 and induces cell death 40 . The expression of K V 3.1 is limited to the CNS, with the exception of a subpopulation of T lymphocytes 41, 42 . It is preferentially expressed in specific subsets of fast-spiking neurons, with prominent expression in inhibitory GABAergic interneurons 28, 41 . Therefore, it is likely that the p.Arg320His substitution in K V 3.1 results in disinhibition due to the impaired firing of fast-spiking GABAergic interneurons. This mechanism is likely to contribute particularly to myoclonus and tonic-clonic seizures. Furthermore, dysfunction and/ or degeneration of cerebellar neurons, where K V 3.1 is expressed 41 , are likely to contribute to motor impairment. Modulation of K V 3 channel function may provide a possibility for pharmacological intervention in patients with KCNC1 mutations. However, although drugs with anticonvulsant effects activating other K V channels exist 43 , there is no activator of K V 3 channels currently available.
The initial clinical presentation and evolution of ULD 44 and the disorder in individuals with the KCNC1 mutation, designated here as 'MEAK' (myoclonus epilepsy and ataxia due to potassium channel mutation), are similar. They have overlapping ages of onset and moderate-to-severe incapacitating myoclonus, infrequent tonic-clonic seizures and mild, if any, cognitive decline. Differences emerge later in disease progression, as the clinical course for MEAK is generally more severe. ULD is caused by mutations in CSTB, encoding cystatin B, which is implicated in oxidative stress and inflammation 45, 46 . Evidence from the mouse model for ULD suggests that altered GABAergic signaling contributes to latent hyperexcitability 47, 48 , implying a possible convergent pathway for ULD and MEAK.
The recurrence of the KCNC1 mutation is likely due to its location in a CpG dinucleotide, corresponding to a class of sites that represent mutation hotspots 49 . We estimated that the mutation occurs in 1 out of 5,700,000 conceptions, thus potentially affecting hundreds of individuals globally. The observation of four cases positive for the KCNC1 mutation ascertained in a multicenter clinical collaboration in Italy 3 supports this estimate, assuming that probably not all existing cases were ascertained and that the mutation might reduce lifespan. We did not observe any other mutations in KCNC1, which is among the top 1% of the most constrained genes 10 . For example, the estimated mutation rates for the three other potential arginineto-histidine substitutions affecting voltage-sensing residues are equal to that for p.Arg320His, and these mutations thus should have been observed in our cohort if the phenotypic consequences were the same. The fact that we only identified the mutation affecting Arg320 suggests that this residue is biophysically special. Indeed, codon-specific consequences of S4-altering mutations have been demonstrated, for example, in K V 3.3 (ref. 31) .
The identification of mutations in previously established diseaserelated genes expands the phenotypic and genotypic spectra of PME. Highlighting the usefulness of exome sequencing as a diagnostic tool in a heterogeneous cohort of affected individuals previously subjected to molecular analyses, we identified pathogenic mutations in known PME-associated genes in ten individuals, of whom the majority had atypical symptoms (Supplementary Table 4 and Supplementary Note). Notably, we identified mutations in three known diseaserelated genes (PRNP, SACS and TBC1D24), where PME has not been appreciated as part of the clinical spectrum. These cases are discussed in the Supplementary Note. The majority of all solved cases also had variants in other known disease-associated genes ( Supplementary  Tables 5 and 6 ). These variants, however, did not fulfill our criteria for pathogenicity. It is possible that they modify the clinical outcome, thus contributing to some atypical disease presentations.
The genetic basis of disease remained unknown in over two-thirds of the cases. Aside from KCNC1, there were no other new PME-related genes definitively identified (Supplementary Tables 2 and 7 , and Supplementary Note); however, of the nine genes with homozygous loss-of-function mutations in single cases, some are interesting candidates (Supplementary Table 8) . In light of de novo mutations being established as an important cause of PME, exome sequencing in a family trio setting could be pursued to further dissect this heterogeneous cohort. Also, the role of copy number variants (CNVs) and epistatic mutations in PMEs should be assessed. Our findings, especially the discovery of MEAK, will aid in molecular diagnostics and potential therapeutic interventions in PME, and the exome data generated will facilitate the further identification of disease-relevant genes. 
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ONLINE METHODS
Study subjects. The study cohort consisted of 84 unrelated individuals with a clinical presentation of PME, collected from multiple centers in Europe, North America, Asia and Australia over a 25-year period for molecular study, where a specific diagnosis had not hitherto been made. Seventy-three cases were of European origin, seven were of West Asian origin, three were of South Asian origin and one was of Chinese origin. The extent of previous molecular investigations varied; mutations in the CSTB gene had been excluded in all, 43 cases tested negative for mutations in SCARB2 and 39 cases tested negative for mutations in GOSR2. A variable set of other genes was also screened for some cases. The study was approved by the institutional review board at the Helsinki University Central Hospital (Finland) and the human research ethics committees of Austin Health (Melbourne, Australia) and the University of South Australia (Adelaide, Australia). Informed consent for DNA analysis was obtained from study participants in line with local institutional review board requirements at the time of collection. Family members, when available, were recruited for segregation analysis, which was carried out using Sanger sequencing.
Seventy cases were sporadic. Three probands had either an affected parent or affected offspring. Ten probands had at least one affected sibling, and one proband had an affected cousin with known parental consanguinity. Fifteen of the cases were reported to be the result of a consanguineous union. On the basis of the inbreeding coefficients obtained with FEstim 56 , the number of cases resulting from consanguinity was 18. No cryptic relatedness between cases (PIHAT > 0.05) was detected by PLINK 57 identity-by-descent (IBD) analysis.
Sanger sequencing was performed on a secondary cohort of 28 cases with PME or possible PME for the KCNC1 recurrent mutation. These cases were excluded from our original cohort for exome sequencing owing to insufficient DNA or inadequate clinical data. Informed consent from study participants in the secondary cohort was obtained as described above for the exome sequencing cohort.
Exome sequencing. Exome sequencing was carried out at the Wellcome Trust Sanger Institute (Hinxton, UK). Genomic DNA (approximately 1 µg) extracted from peripheral blood for each sample was fragmented to an average size of 150 bp and subjected to DNA library creation using established Illumina paired-end protocols. Adaptor-ligated libraries were amplified and indexed via PCR. A portion of each library was used to create an equimolar pool comprising 4-8 indexed libraries. Each pool was hybridized to SureSelect Human All Exon 50Mb V3 RNA baits (Agilent Technologies), and sequence targets were captured and amplified in accordance with the manufacturer's recommendations. Enriched libraries were subjected to 75-base paired-end sequencing (HiSeq 2000, Illumina) following the manufacturer's instructions. Each pool of indexed samples was sequenced twice on two different flow cells.
Sequence read alignment and processing. Alignment of the sequenced DNA fragments to the human reference genome was performed using the BurrowsWheeler Alignment Tool (BWA) 58 . The reference sequence used was the 1000 Genomes Project Phase II reference (hs37d5), which is based on GRCh37 and consists of chromosomes 1-22, X and Y, as well as the mitochondrial genome (rCRS mitochondrial sequence NC_012920), unlocalized and unplaced contigs, human herpesvirus 4 type 1 (NC_007605) and decoy sequences derived from HuRef, human BAC and fosmid clones and NA12878.
Duplicate reads were marked using the Picard toolkit. Sequence reads were further processed using Genome Analysis Toolkit (GATK) software (version 2.8.1) 59,60 on the basis of GATK best practices. Specifically, local realignment was performed around known insertion or deletion (indel) locations, and base quality scores were recalibrated.
Variant calling. SNVs and indels were called for all exomes jointly using the GATK HaplotypeCaller. Called variants with a quality score of >30 were accepted. Variant quality scores for the PME exomes were recalibrated jointly with the GATK VariantRecalibrator. HapMap 3.3 and the Omni 2.5M SNP chip array from the 1000 Genomes Project were used as truth site training resources in the variant quality score recalibration (VQSR) of SNVs. Mills and 1000 Genomes Gold Standard indels were used as truth sites in indel VQSR. A truth sensitivity cutoff of 99.0% was used for both SNVs and indels. Additional filtering was applied to exclude variant sites where >80% of the samples had <5× read depth. Individual variant calls with a read depth below 5× were excluded.
Variant filtering under recessive and dominant/de novo inheritance models. Considering the different possible inheritance patterns of the underlying mutations in the study subjects, we aimed to identify autosomal or sex-linked recessive and dominant (including de novo) mutations as well as pathogenic changes in the mitochondrial genome (Fig. 1) . We considered coding variants with the following Variant Effect Predictor 61 (Ensembl release 75) annotated variant consequences based on Sequence Ontology nomenclature: missense variant, initiator codon variant, splice donor or acceptor variant, stop lost, stop gained, in-frame insertion or deletion (in-frame indels in tandem repeat regions 62 obtained from the UCSC Genome Browser 63 were excluded) and frameshift variant. If there were multiple Ensembl gene transcripts overlapping the variant site, the transcript having the most severe consequence annotation for the variant was selected while prioritizing Ensembl database canonical transcripts. Only variants within the genes included in the December 2013 version (release 15) of the Consensus CDS (CCDS) project, implemented in Ensembl release 75, were considered. To exclude likely benign amino acid changes, missense variants were considered only if two or more of the four in silico methods predicted the variant to be deleterious: CADD 64 (Phred-like scaled C score > 15, which is a suggested threshold for deleteriousness by the authors), PolyPhen-2 HumVar 65 (possibly damaging or probably damaging), SIFT 66 (deleterious) and MutationTaster 67 (disease causing; MutationTaster prediction scores were obtained using dbNSFP 68 and correspond to the converted score suggested by the authors). In rare cases, when not all of the four prediction methods could be applied, we accepted missense mutations predicted to be deleterious by at least 50% of the available methods. We also analyzed the exome data using only CADD to evaluate the deleteriousness of silent or noncoding mutations (Supplementary Note).
In recessive filtering, we included homozygous, hemizygous or compound heterozygous variants with allele frequencies of <1% in the 3 following variant databases: 1,092 exomes from the phase I release of the 1000 Genomes Project 69 , 6,503 exomes from EVS in the NHLBI GO Exome Sequencing Project (version 0.0.25) and 3,268 Finnish exomes (Sequencing Initiative Suomi project, SISu; only autosomal SNVs, with epilepsy cases removed). Variants present in a homozygous or hemizygous state in any of the three variant databases were excluded. As we did not carry out exome sequencing of parental samples, we used three methods for phasing genotypes to facilitate the identification of compound heterozygous variants. First, physical phasing of SNV calls, based on the presence of heterozygous variants in the same sequencing reads, was performed using GATK ReadBackedPhasing. Because the ReadBackedPhasing method handles only SNVs, heterozygous indels present in the same sequencing reads were manually removed. Second, to detect rare variants segregating together in populations (likely to be inherited from only one parent), Beagle 70 was applied to phase genotypes using 1000 Genomes Project Phase I data as a reference. Third, we used genotype information from the 3,268 Finnish exomes to detect heterozygous variants likely to be on the same allele. After filtering the variant data using a recessive hypothesis, before taking advantage of the phasing information, we visualized the sequencing reads surrounding the variants that passed filtering using the Integrative Genomics Viewer 71 (IGV) to detect likely false positive calls residing mainly within segmental duplication regions where mapping of reads is more challenging. As a technical comparison set for variant visualization, we used 43 in-house exomes that had been processed in the same sequencing, read processing and variant calling pipelines as the exomes in this study. After excluding low-quality variants, we implemented the phasing information in the cleaned data and repeated the recessive filtering.
In the dominant/de novo filtering strategy, we assumed full penetrance of the mutations and, because the great majority of cases had disease onset before adulthood (10/84 cases had onset at 18 years or older, maximum onset age of 26 years), we included heterozygous variants absent from the three variant databases. Additionally, dbSNP Build 138 variants were excluded except those with clinical association in NCBI ClinVar. After applying the filtering criteria, we excluded low-quality variants on the basis of IGV visualization of sequencing reads as described for the filtering of recessive variants.
npg Analysis of filtered variant data under recessive and dominant/de novo strategies. Exome data were analyzed both for variants in genes previously associated with PME, epilepsy and/or neurodegenerative disorders and variants in new genes. The association of genes with mendelian diseases was annotated on the basis of the OMIM database 72 . Additionally, genes involved in monogenic forms of epilepsy and neurodegenerative disease were retrieved on the basis of the diagnostic panels developed by Lemke and colleagues 73 . Genes involved in PME were also retrieved from the literature.
To identify new recessive or dominant/de novo genetic causes, genes with variants surviving the filtering strategy were ranked on the basis of the number of PME cases with variants in the gene. Genes that are highly polymorphic in human populations and were thus likely to rank high in the data analysis only as a result of their high benign mutational load were given less priority if at least one of the following criteria was fulfilled: (i) the gene had a residual variation intolerance score (RVIS) 74 (estimating the tolerance of genes for functional variation) in the most tolerant tenth percentile (this criterion was used only in the dominant/de novo model) and (ii) the gene was identified as hyperpolymorphic by Fuentes Fajardo and colleagues 75 . Other measures used in the prioritization of candidate genes and variants were known disease association and the function (UniProt database 76 and the literature) and expression pattern (GTEx database 42 and the literature) of the gene.
Analysis of mitochondrial DNA variants. Because PME might also be caused by mutations in the mitochondrial genome 77 , we analyzed the mtDNA for possible disease-associated mutations. Even though baits for mtDNA are not included in the SureSelect exome capture kit, we obtained an average of 32.7× sequencing coverage per sample in the mitochondrial genome, owing to the abundance of mtDNA in cells. We called mtDNA variants using the GATK UnifiedGenotyper. At sites for the most commonly reported mutations associated with diseases showing myoclonus as part of the clinical presentation, namely myoclonic epilepsy with ragged red fibers (MERRF) and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), the average coverage was at least 24.8×. We searched for new mitochondrial mutations by excluding known mtDNA polymorphisms in the MITOMAP database. The same database was also used to obtain positions for known disease-associated mtDNA mutations.
Classification criteria for mutations in known as well as new diseaseassociated genes. We used a three-tier scale to classify mutations passing variant filtering in genes known to be associated with PME, epilepsy or neurodegenerative disease: (i) pathogenic, (ii) probably pathogenic and (iii) unlikely to be pathogenic. Classification criteria were as follows.
Pathogenic. The mutation was in a known PME-associated gene, i.e., where mutations cause a disease with PME as a key feature of the presentation, or in a gene known to be associated with epilepsy or neurodegenerative disease, had previously been reported as pathogenic and corresponded to a phenotype in the case that was compatible to those of previous cases. In addition, the mutation was required to map to a conserved domain where other pathogenic mutations had previously been reported. Segregation data, when available, had to comply with the expected inheritance pattern in the family, and the mode of inheritance had to concur with that for previously reported cases. If no segregation data were available, the corresponding phenotype had to present substantial overlap with those of previously reported cases, and, in the case of previously reported pathogenic compound heterozygous mutations, the mutations should not have occurred in cis in the original report.
Probably pathogenic. Either the mutation occurred in only one case in a previously established disease-related gene with phenotypic overlap with PME or occurred in a previously established neurological disease gene with little phenotypic overlap with PME and two or more cases had mutations in the gene. In addition, the mutation was required to map to a conserved domain where other pathogenic mutations had been reported previously. Segregation data for the mutation had to comply with the expected inheritance pattern in the family, and the mode of inheritance had to concur with that for previously reported cases.
Unlikely to be pathogenic. This category included mutations that did not fulfill the above criteria.
To consider new disease-associated genes as candidates for PME, we required them to harbor mutations in at least two cases in the recessive variant filtering strategy and in at least four cases in the dominant/de novo variant filtering strategy. The higher threshold in the dominant/de novo strategy was set to limit the number of candidates to a feasible level for follow-up, as exome variant data for the parents were not available for filtering inherited variants in data analysis.
Variant validation and segregation analysis. Candidate mutations in known and new disease-associated genes were confirmed and segregation of the variants was analyzed, when DNA from parents or siblings was available, by bidirectional Sanger sequencing (ABI BigDye 3.1, Applied Biosystems) on an ABI 3730xl DNA Analyzer. Primers (sequences available from the authors upon request) were designed with Primer-BLAST 78 . Sequences were analyzed using Sequencher (Gene Codes Corporation) and visualized using 4Peaks (Nucleobytes). Evaluation of the quality of the sequence reads over the recurrent c.959G>A mutation in KCNC1 is described in the Supplementary Note.
Parental testing of the cases with the c.959G>A mutation in KCNC1. Parental testing was carried out for five cases (those with a sufficient amount of parental DNA available) with the de novo c.959G>A mutation in KCNC1 to exclude false paternity and inadvertent sample substitution. Biparental testing was performed using 12 highly polymorphic microsatellite markers: D3S3680, D4S418, D6S289, D7S2560, D8S281, D13S175, D13S221, D15S117, D19S1150, DXS1113, DXS1036 and DXS7423. PCR was performed using the Qiagen Multiplex PCR kit according to the manufacturer's instructions. The reverse primer of each pair was labeled with either HEX or FAM. Products were analyzed on an ABI 3131 Genetic Analyzer.
Analysis of parental mosaicism for the c.959G>A mutation in KCNC1 in the family of PME84-1. The PCR product corresponding to exon 2 of KCNC1 was amplified using the same primers and conditions as for sequencing, and 10 µl of the PCR reaction was digested with 2 U HpyCH4V (New England BioLabs) for 2 h at 37 °C under the conditions recommended by the manufacturer. Fragments were visualized by electrophoresis of 10 µl of the digest on a 2% agarose gel in TBE buffer. Gels were stained with RedSafe (INtRON Biotechnology). PCR and digestion were performed in duplicate.
Evaluation of the expected rate of mutations encoding arginine-to-histidine changes in the S4 segment of K V 3.1. The expected rates for the four possible mutations encoding arginine-to-histidine changes (CGC>CAC) in the voltagesensing arginine residues of the K V 3.1 S4 segment (p.Arg311His, p.Arg314His, p.Arg317His and p.Arg320His; Fig. 2b,c) were established using a recently developed statistical framework 10 , which takes into account both the local sequence context of a mutation site and regional factors such as divergence between humans and macaques.
Functional analysis of the p.Arg320His substitution in K V 3.1. Mutagenesis and RNA preparation. We used the QuikChange kit (Stratagene) to engineer the missense mutation c.959G>A (p.Arg320His) into human KCNC1 cDNA (NM_004976; this construct corresponds to the K V 3.1a isoform (511 amino acids), which has a shorter cytoplasmic C-terminal domain but identical biophysical properties in comparison to the longer K V 3.1b (585 amino acids) isoform 79 ) cloned in a pCMV-Entry vector obtained from OriGene Technologies. This clone encodes a C-terminal Myc-DDK tag. Introduction of the mutation was confirmed and the presence of additional mutations was excluded by Sanger sequencing. Primer sequences are available upon request. cRNA was prepared using the T7 mMessage mMachine kit from Ambion.
Oocyte preparation and injection. The use of animals and all experimental procedures were approved by local authorities (Regierungspraesidium Tübingen, Tübingen, Germany). Extracted ovary pieces (X. laevis) obtained from the Institute of Physiology I, Tübingen, were treated with collagenase (1 mg/ml type CLS II collagenase, Biochrom) in OR-2 solution (82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl 2 and 5 mM HEPES, pH 7.6), washed thoroughly and stored at 16 °C in Barth solution (88 mM NaCl, 2.4 mM NaHCO 3 , 1 mM npg
